CG
ORMP icon

Cutler Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Cutler Group’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300
Closed -$2K – 4455
2022
Q4 		$2K Sell
300
-100
-25% -$777 ﹤0.01% 3734
2022
Q3 		$1K Buy
+400
New +$3.24K ﹤0.01% 4623
2022
Q2 		– Sell
-7,000
Closed -$2K – 5469
2022
Q1 		$2K Sell
7,000
-28,600
-80% -$293K ﹤0.01% 4725
2021
Q4 		$20K Buy
35,600
+25,000
+236% +$523K ﹤0.01% 3127
2021
Q3 		$58K Buy
+10,600
New +$181K ﹤0.01% 2392
2016
Q4 		– Sell
-13,100
Closed -$1K – 7091
2016
Q3 		$1K Sell
13,100
-2,900
-18% -$22.5K ﹤0.01% 6225
2016
Q2 		$11K Buy
16,000
+14,000
+700% +$119K ﹤0.01% 4032
2016
Q1 		$1K Sell
2,000
-5,000
-71% -$33.5K ﹤0.01% 6078
2015
Q4 		$7K Buy
+7,000
New +$53.1K ﹤0.01% 4567

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SIGI
Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cutler Group's ORMP Position: Q1 2023 in Review

Cutler Group sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 1,713 shares — an estimated $20K sold.

Cutler Group first reported a position in ORMP in Q4 2015 and held it in 11 quarters. The position peaked at $130K in Q1 2016. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

  • Cutler Group reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cutler Group sold 1,713 Oramed Pharmaceuticals shares in Q1 2023, an estimated $20K.
  • Cutler Group first reported a position in Oramed Pharmaceuticals in Q4 2015 and held it in 11 quarters.
  • Cutler Group's Oramed Pharmaceuticals position peaked at $130K in Q1 2016.
  • 61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Cutler Group's 13F filing for Q1 2023, filed 1 May 2023.